Prescribing in borderline personality disorder – the clinical guidelines
Progress in Neurology and Psychiatry · 2020-04 · 24 (2) · 25-30
DOI: 10.1002/pnp.667 ↗Abstract
Drug prescription and polypharmacy are commonly seen in the management of borderline personality disorder (BPD) in clinical practice, and the ‘placebo effect of medications’ in BPD patients is significant. However, it is to be noted that ‘no drug’ has a UK market authorisation or Food & Drug Administration approval in the USA for BPD. Here Dr Yadav reviews the guidelines.
EUVIMED